Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07365709CT.gov Liver Cirrhosis Complicated by Clinically Significant Portal Hypertension | — | Not Yet Recruiting | — | — | — |
NCT04006275CT.gov Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC | — | Unknown | — | — | — |
NCT03407001CT.gov Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cirrhosis Of Liver
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sulfur Hexafluoride (this asset) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | B · 57 |
| Veruprevir | AbbVie | P3 | A |
| Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) | General Hospital of Shenyang Military Region | P4 | BBB |
| Tolvaptan | Institute of Liver and Biliary Sciences, India | P4 | BBB |
| Normal Human Serum Albumin | King George's Medical University | P4 | BBB |
| Cholyl-Lysl-Fluorescein | Norgine | P3 | BBB |
| Ribavirin | Peking University People's Hospital | P4 | BBB |
| Ombitasvir | AbbVie | P3 | BBB |
| Simvastatin | Chang Gung Memorial Hospital | P4 | BBB |
+42 more in the Cirrhosis Of Liver cohort
Other indications for Sulfur Hexafluoride
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BB · 67 |
| Stroke Disorder | — | P2 | B · 62 |
| Carotid Stenosis | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sulfur Hexafluoride in Cirrhosis Of Liver. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sulfur-hexafluoride-cirrhosis-of-liver
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →